Genotoxicity Assessment for Patients Undergoing Radiation Treatment
| Status: | Recruiting |
|---|---|
| Conditions: | Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 1/5/2019 |
| Start Date: | April 2006 |
| End Date: | October 2023 |
| Contact: | Therese Smudzin, BS |
| Email: | therese_smudzin@urmc.rochester.edu |
| Phone: | 585-275-7848 |
Genotoxicity Assessment for Patients Receiving Large Field Irradiation
The purpose of the research study is to evaluate an automated, laser-based technique for
measuring DNA damage caused by radiation during cancer treatment in immature red blood cells.
measuring DNA damage caused by radiation during cancer treatment in immature red blood cells.
Correlative studies: analysis of RT effect on genotoxicity by assessing cytogenetic changes
(dicentrics), micronucleated lymphocytes (MN-lymph), and micronucleated reticulocytes
(MN-RET) using peripheral blood of patients receiving radiation.
i) document the kinetics by which radiation-induced MN-RET enter the peripheral blood stream.
ii) benchmark the MN-RET endpoint against current gold-standard biodosimetry
endpoints—dicentrics and MN-lymphocytes.
iii) measure inter-individual variation in baseline and radiation-induced MN-RET frequencies.
iv) in collaboration with several FCM-equipped laboratories, evaluate the transferability of
the human MN-RET scoring assay.
(dicentrics), micronucleated lymphocytes (MN-lymph), and micronucleated reticulocytes
(MN-RET) using peripheral blood of patients receiving radiation.
i) document the kinetics by which radiation-induced MN-RET enter the peripheral blood stream.
ii) benchmark the MN-RET endpoint against current gold-standard biodosimetry
endpoints—dicentrics and MN-lymphocytes.
iii) measure inter-individual variation in baseline and radiation-induced MN-RET frequencies.
iv) in collaboration with several FCM-equipped laboratories, evaluate the transferability of
the human MN-RET scoring assay.
Inclusion Criteria:
- Patients that are scheduled to begin radiotherapy to the large-field chest region are
eligible if:
- Daily radiation dose is between 1.8 and 5 Gy/day
- Any single dimension of field size is ≥ 15 cm
- Provision of written informed consent
or
- Or patients receiving IMRT or Tomotherapy, when low-dose radiation is spread out to
the normal tissues, irrespective of daily radiation doses.
- Or patients receiving radionucleotides as part of the medical treatment (cancer or
non-malignant conditions)
- Or patients who will receive diagnostic CT scans, PET/CT scans, mammograms, or
diagnostic imaging requiring radionucleotides
We found this trial at
1
site
Rochester, New York 14642
Principal Investigator: Yuhchyau Chen, MD, Ph.D
Click here to add this to my saved trials
